Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Journal of Clinical Pharmacology|February 24, 2006
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteersAnup K Majumdar, Laura Howard, Michael R Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeksS G Eckhardt, S D Baker, J R Eckardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Journal of Clinical Pharmacology|February 24, 2006
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteersAnup K Majumdar, Laura Howard, Michael R Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeksS G Eckhardt, S D Baker, J R Eckardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
Pageof 17